See today's BioWorld
To read the full story, subscribe or sign in.

Santhera, Catalyst look beyond DMD with $231M vamorolone collaboration

June 20, 2023
By Nuala Moran
With its Duchenne muscular dystrophy (DMD) drug, vamorolone, under U.S. FDA review, Santhera Pharmaceutical AG has signed a $231 million-plus-royalties North America commercialization deal with Catalyst Pharmaceuticals Inc.
BioWorld Deals and M&A License